Basic Science Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Front Immunol. 2018 Mar 6;9:443. doi: 10.3389/fimmu.2018.00443. eCollection 2018.
The TNFR2 receptor is expressed by highly active regulatory T cells, and thus constitutes an important therapeutic target for the treatment of autoimmune disease and cancer. Disease susceptibility as well as the potential response to therapies directed at TNFR2 could be significantly impacted by genetic variation in the promoter of the gene that codes for the TNFR2 protein. To date, only a few studies have examined the association of promoter variation with disease, and the potential impact on T-regulatory cell (Treg) number and function has not been examined. We propose that copy number variation of a key transcription factor binding site has a significant effect on promoter activity, and should be considered in studies of disease susceptibility and especially with regard to variation in the level of TNFR2 expression on Tregs.
TNFR2 受体由高活性调节性 T 细胞表达,因此是治疗自身免疫性疾病和癌症的重要治疗靶点。TNFR2 蛋白编码基因启动子的遗传变异可能显著影响疾病易感性以及对针对 TNFR2 的治疗的潜在反应。迄今为止,只有少数研究检查了 基因启动子变异与疾病的关联,也没有检查其对调节性 T 细胞 (Treg) 数量和功能的潜在影响。我们假设关键转录因子结合位点的拷贝数变异对 启动子活性有显著影响,应在疾病易感性研究中考虑这一点,尤其是在 Treg 上 TNFR2 表达水平的变异方面。